miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway

Related Experiment Video

Updated: Feb 17, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

Ping Wang1, Qunye Guan2, Dongmei Zhou1

  • 11 Department of Oncology, Yantaishan Hospital , Yantai, China .

DNA and Cell Biology
|November 30, 2017
PubMed

Insights

Inhibiting miR-21, a microRNA overexpressed in gastric cancer, suppressed tumor cell growth, migration, and invasion. This suggests miR-21 inhibitors could be a novel therapeutic strategy for gastric cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastric cancer is a prevalent global malignancy.
  • MicroRNAs (miRNAs) regulate gene expression and are implicated in cancer.
  • miR-21 is frequently overexpressed in gastric cancer, suggesting a role in tumorigenesis.

Purpose of the Study:

  • To investigate the effects of a miR-21 inhibitor on gastric cancer cell functions.
  • To elucidate the underlying molecular mechanisms, particularly the PTEN/PI3K/mTOR pathway.

Main Methods:

  • Gastric cancer cells (MKN74) were treated with a miR-21 inhibitor.
  • Assessed cell proliferation, colony formation, migration, and invasion.
  • Utilized real-time PCR and western blot to analyze PTEN/PI3K/mTOR pathway components and Bcl-2/Bax ratio.

Main Results:

  • miR-21 inhibition significantly suppressed gastric cancer cell proliferation, migration, invasion, and colony formation.
  • Treatment reduced the Bcl-2/Bax expression ratio, indicating apoptosis induction.
  • miR-21 inhibition increased PTEN expression, leading to decreased phosphorylation of AKT (p-AK/AKT) and downstream signaling.

Conclusions:

  • Inhibition of miR-21 effectively modulates biological functions of gastric cancer cells.
  • The mechanism involves the regulation of the PTEN/PI3K/mTOR pathway.
  • miR-21 inhibitors represent a potential novel therapeutic strategy for gastric cancer.
Keywords:
MKN74PTENgastric cancermiR-21

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K